Advaxis, Inc. Completes Dosing of Vanguard Patient Group in Phase II Cervical Dysplasia Clinical Trial
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) biotechnology company, enrolled and has administered its initial dose to its third patient in its US Food and Drug Administration (FDA)-approved, phase II clinical trial in cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia. This completes the enrollment of the vanguard group of patients for the first dosage group.